{
  "id": "doc:hse.00857",
  "type": "Document",
  "documentType": "Regulatory approval",
  "name": "Pembrolizumab 200mg, CARBOplatin AUC 5 and weekly PACLitaxel 80mg/m 2 followed by DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy. NCCP National SACT Regimen. HSE.",
  "title": null,
  "aliases": [],
  "description": "Pembrolizumab 200mg, CARBOplatin AUC 5 and weekly PACLitaxel 80mg/m 2 followed by DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy, 2024, version number 1, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/857-pembrolizumab-200mg-carboplatin-auc-5-and-weekly-paclitaxel-80mg-m2-followed-by-doxorubicin-and-cyclophosphamide.pdf",
  "urls": [
    "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/857-pembrolizumab-200mg-carboplatin-auc-5-and-weekly-paclitaxel-80mg-m2-followed-by-doxorubicin-and-cyclophosphamide.pdf"
  ],
  "doi": null,
  "pmid": null,
  "extensions": [
    {
      "name": "agent",
      "value": {
        "id": "hse",
        "type": "Agent",
        "agentType": "organization",
        "name": "Health Service Executive",
        "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland.",
        "extensions": [
          {
            "name": "last_updated",
            "value": "2025-10-01",
            "description": ""
          },
          {
            "name": "url",
            "value": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/",
            "description": ""
          }
        ]
      },
      "description": "The organization that published this document."
    },
    {
      "name": "company",
      "value": "",
      "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
    },
    {
      "name": "drug_name_brand",
      "value": null,
      "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
    },
    {
      "name": "drug_name_generic",
      "value": null,
      "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
    },
    {
      "name": "first_publication_date",
      "value": null,
      "description": "The publication date for the initial version of this document."
    },
    {
      "name": "identification_number",
      "value": null,
      "description": "Identification number used by the publishing organization."
    },
    {
      "name": "publication_date",
      "value": "2024-06-04",
      "description": "The publication date for the document."
    },
    {
      "name": "status",
      "value": "Active",
      "description": "Whether this document is Active or Deprecated within moalmanac-db."
    }
  ]
}